AstraZeneca Pharma India accepts resignation of Dr. Sandeep Arora
- Dr. Sandeep Arora resigned as Director – Medical Affairs effective September 15, 2026
- He led medical affairs for the Biopharmaceutical and Rare Disease Business Units
- The company disclosed the change under SEBI Listing Regulations Regulation 30
- AstraZeneca Pharma India is seeking a suitable replacement for the role
*this image is generated using AI for illustrative purposes only.
AstraZeneca Pharma accepted the resignation of Dr. Sandeep Arora as Director – Medical Affairs, effective September 15, 2026. The executive will leave to pursue career opportunities outside the organization.
Dr. Arora served as Director – Medical Affairs for the Biopharmaceutical Business Unit and Rare Disease Business Unit. He completed his handover period and was relieved from duties by the close of business hours on the effective date.
Regulatory Disclosure
The company disclosed the change pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information was submitted to both the BSE Limited and the National Stock Exchange of India Limited.
The filing references SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, regarding Senior Management Personnel changes. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on September 15, 2026.
Succession Plans
AstraZeneca Pharma India Limited stated it is in the process of looking for a suitable replacement for the position. The resignation letter, enclosed as Annexure A, confirmed Dr. Arora’s decision to exit the company.
Historical Stock Returns for AstraZeneca Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.83% | -4.37% | -16.43% | -24.20% | -26.80% | 0.0% |
How might the interim leadership structure for the Biopharmaceutical and Rare Disease units impact ongoing clinical trials or regulatory submissions during the search for a permanent replacement?
Could Dr. Arora's departure signal a broader strategic shift in AstraZeneca India's medical affairs approach, particularly regarding its rare disease portfolio?
What is the expected timeline for appointing a new Director, and will the company consider internal promotions versus external hires to ensure continuity in key therapeutic areas?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
